PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

oseltamivir Side Effects

The reactions most often reported to the FDA for oseltamivir (also sold as Tamiflu), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

7,575
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of oseltamivir come from 7,575 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 7,575 reports to the FDA Adverse Event Reporting System (FAERS) for oseltamivir (Tamiflu): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

7,575

Reports Mentioning Death

1,149

15.2% of reports — not proof the medicine caused the death

Hospitalizations

2,529

33.4% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

VOMITING
444
NAUSEA
443
HEADACHE
381
PNEUMONIA
368
CONDITION AGGRAVATED
332
INFLUENZA
330
DYSPNOEA
283
ABDOMINAL PAIN
280
SEPSIS
260
DIARRHOEA
259
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION
254
PYREXIA
250
MULTIPLE ORGAN DYSFUNCTION SYNDROME
246
HYPERSENSITIVITY
243
GENERAL PHYSICAL HEALTH DETERIORATION
226

Who Reports Side Effects

Gender Distribution

Female 3,332 (51%)
Male 3,149 (48%)
Unknown 18

Age Distribution

0-17 811 (16%)
18-44 1,592 (31%)
45-64 1,362 (27%)
65-74 631 (12%)
75+ 708 (14%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 1,149 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
MULTIPLE ORGAN DYSFUNCTION SYNDROME 234
SEPSIS 219
DEATH 211
HYPONATRAEMIA 211
CONDITION AGGRAVATED 203
GENERAL PHYSICAL HEALTH DETERIORATION 201
NAUSEA 193
VOMITING 193
ASCITES 190
STRESS 190
ABDOMINAL DISTENSION 188
APPENDICITIS 186
APPENDICOLITH 184
CARDIOGENIC SHOCK 184
ABDOMINAL PAIN 181
VENTRICULAR FIBRILLATION 178
CONSTIPATION 174
SOMNOLENCE 152

Reactions in Hospitalization Reports

Top reactions in 2,529 reports where hospitalization was an outcome.

Reaction Reports
PNEUMONIA 268
CONDITION AGGRAVATED 232
NAUSEA 206
INFLUENZA 196
VOMITING 194
DYSPNOEA 190
ABDOMINAL PAIN 169
SEPSIS 166
PYREXIA 159
ANAEMIA 158
HYPONATRAEMIA 148
MULTIPLE ORGAN DYSFUNCTION SYNDROME 148
PULMONARY EMBOLISM 142
GENERAL PHYSICAL HEALTH DETERIORATION 138
SOMNOLENCE 131
ABDOMINAL DISTENSION 128

Compare oseltamivir vs acyclovir →

What the FAERS Data Reveals About oseltamivir Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 7,575 voluntary reports linked to oseltamivir and its brand equivalents (Tamiflu), spanning 2004 through 2025. Of those, 1,149 (15.2%) listed death as an outcome and 2,529 (33.4%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 51% were female and 48% male; age distribution skews toward 18-44, with 1,592 reports in that bracket. The single most reported reaction is vomiting with 444 submissions, followed by nausea and headache.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.